Publisher： Bentham Science Publishers
E-ISSN： 1873-4316|13|12|2403-2416
ISSN： 1389-2010
Source： Current Pharmaceutical Biotechnology, Vol.13, Iss.12, 2012-09, pp. : 2403-2416
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Despite advances in surgery and drug discovery, brain tumors remain fatal diseases. Early detection and diagnosis of brain tumors is of great importance for improving treatment outcomes. Magnetic resonance imaging (MRI) is a prominent, clinically-relevant imaging modality because of its excellent tissue contrast resolution, direct multiplanar imaging and increased sensitivity to edema. MRI utility is further enhanced with the use of magnetic iron oxide nanoparticles, which can function as both a contrast agent for imaging and as a drug delivery vehicle for treating brain cancer. In this review, the principles of various imaging modalities for brain tumors are discussed with focus on monocrystalline iron oxide nanoparticle (MION)-based MRI contrast agents. A summary is given on the mechanism of contrast effect, magnetophoretic mobility and magnetic retention, and strategies to enhance tumor selectivity, increase spatial resolution and reduce nonspecific uptake of MION.
Related content
Recent Developments of Magnetic Nanoparticles for Theranostics of Brain Tumor
Current Drug Metabolism, Vol. 17, Iss. 8, 2016-08 ,pp. :
Access to resources
Recommend
The Toolbox of Designing Nanoparticles for Tumors
Mini Reviews in Medicinal Chemistry, Vol. 14, Iss. 9, 2014-07 ,pp. :
Ion Transporters in Brain Tumors
Current Medicinal Chemistry, Vol. 22, Iss. 10, 2015-04 ,pp. :